AG
ALDR

Aperio Group’s Alder Biopharmaceuticals ALDR Stock Holding History

Aperio Group’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,862
Closed -$22K – 3003
2019
Q2 		$22K Buy
+1,862
New +$22.5K ﹤0.01% 2683

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aperio Group's ALDR Position: Q3 2019 in Review

Aperio Group sold out of Alder Biopharmaceuticals (ALDR) in Q3 2019, closing a stake of 1,862 shares — an estimated $22K sold.

Aperio Group first reported a position in ALDR in Q2 2019 and held it in 1 quarter. The position peaked at $22K in Q2 2019. 143 funds tracked by Wall St. Rank hold ALDR as of Q3 2019.

  • Aperio Group reported no remaining Alder Biopharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 1,862 Alder Biopharmaceuticals shares in Q3 2019, an estimated $22K.
  • Aperio Group first reported a position in Alder Biopharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Aperio Group's Alder Biopharmaceuticals position peaked at $22K in Q2 2019.
  • 143 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.